15 results
8-K
EX-99.2
GLUE
Monte Rosa Therapeutics Inc
9 May 24
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
7:05am
surface-based algorithms design MGDs to recruit targets. Our platforms generate actionable data-at-scale to test & train (“data moat”) Our Critical
8-K
EX-99.2
GLUE
Monte Rosa Therapeutics Inc
14 Mar 24
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:05am
learning algorithms use surfaces to predict targets. Our surface-based algorithms design MGDs to recruit targets. Our platforms generate actionable
424B5
GLUE
Monte Rosa Therapeutics Inc
26 Oct 23
Prospectus supplement for primary offering
4:55pm
recruit neosubstrates to E3 ligases utilizing degrons discovered through our experimental platform and AI approach.
Our lead candidate, MRT-2359
S-3
l125b raic6ansbv55s
1 Jul 22
Shelf registration
5:01pm
10-K
g79rs0 qgk
29 Mar 22
Annual report
4:15pm
10-Q
n7ruy7
12 Aug 21
Quarterly report
4:22pm
424B4
0oh3 b90d5
25 Jun 21
Prospectus supplement with pricing info
6:08am
S-1/A
sst2q58jypf o2
9 Jun 21
IPO registration (amended)
4:51pm
S-1
vnn2v4xerb4kncx61
4 Jun 21
IPO registration
9:07am
DRS/A
veoq98twp7ty7h
21 May 21
Draft registration statement (amended)
12:00am
DRS
q34awsv0sw6wdfv
19 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next